Core Insights - Gemini Space Station raised $425 million in an initial public offering (IPO) [1] - The stock was priced above the marketed range, indicating strong demand [1] - The number of shares offered was reduced, which may reflect a strategic decision to enhance stock value [1] Financial Summary - The total amount raised in the IPO was $425 million [1] - The pricing strategy involved setting the stock price above the initially marketed range, suggesting positive market sentiment [1] - The reduction in the number of shares offered could imply a focus on maintaining a higher stock price post-IPO [1]

Gemini raised $425 million in an initial public offering, pricing its stock above a marketed range and shrinking the number of shares, according to a person familiar with the matter https://t.co/dAfdvXCuwW ...

Core Points - Trailblazer Acquisition Corp. successfully closed its upsized initial public offering (IPO) of 27,500,000 units, generating gross proceeds of $275,000,000 at a price of $10.00 per unit [1][3] - The units began trading on Nasdaq under the ticker symbol "BLZRU" on September 10, 2025, with each unit comprising one Class A ordinary share and one-third of a redeemable warrant [2] - The company is a blank check entity aiming to pursue mergers or acquisitions primarily in the media and communications, sports and entertainment, technology, and consumer retail sectors [4] Financial Details - The IPO included a partial exercise of the underwriters' over-allotment option, resulting in the issuance of an additional 3,500,000 units [1] - A total of $275,000,000 from the IPO proceeds was placed in a trust account for the company [3] Management and Structure - The management team is led by CEO Eric Semler and CFO Eamon P. Smith, with a board that includes Thomas J. Lee, Thomas S. ("Tad") Smith, Jr., and Steven Silverstein [5] - Cantor Fitzgerald & Co. served as the sole book-running manager for the offering [5]

Gemini is telling investors it expects to cap the base size of its initial public offering at $425 million ahead of pricing later on Thursday, according to sources https://t.co/Ro98IZJehp ...

The window for initial public offerings in Europe has opened in earnest this week, with a flurry of listings indicating the tariff-induced caution that disrupted deals earlier in the year has passed https://t.co/CqPHOkk5OY ...

Company Overview - LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases [5] - The company is advancing its lead product candidate, LB-102, which aims to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States [5] - LB-102 is positioned to potentially become a mainstay in psychiatric practice, offering an alternative to existing branded and generic therapeutics [5] Initial Public Offering (IPO) Details - LB Pharmaceuticals announced the pricing of its upsized initial public offering of 19,000,000 shares at a public offering price of $15.00 per share, expecting gross proceeds of $285.0 million before expenses [1] - The offering includes a 30-day option for underwriters to purchase an additional 2,850,000 shares at the initial public offering price [1] - Shares are set to begin trading on the Nasdaq Global Market under the ticker symbol "LBRX" on September 11, 2025, with the offering expected to close on September 12, 2025 [2] Regulatory and Compliance Information - A registration statement on Form S-1 has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on September 10, 2025 [3] - The offering is being conducted only through a written prospectus, with copies available from the joint bookrunning managers [3]

Core Points - Talon Capital Corp. successfully closed its initial public offering (IPO) of 24,900,000 units at a price of $10.00 per unit, raising total gross proceeds of $249,000,000 before expenses on September 10, 2025 [1] - The units began trading on Nasdaq under the ticker symbol "TLNCU" on September 9, 2025, with each unit consisting of one Class A ordinary share and one-third of a redeemable public warrant [2] - Cohen & Company Capital Markets served as the lead book-running manager for the public offering [3] Additional Information - A registration statement for the securities became effective on September 8, 2025 [4] - The press release includes forward-looking statements regarding the anticipated use of net proceeds from the offering [5] - Contact information for Talon Capital Corp. is provided for further inquiries [6]

Core Viewpoint - Zenta Group Company Limited has successfully completed its initial public offering, raising a total of $6 million by offering 1,500,000 ordinary shares at a price of $4.00 per share, with plans to utilize the proceeds for business expansion and development in various regions [1][3]. Group 1: Offering Details - The initial public offering consisted of 1,500,000 ordinary shares priced at $4.00 each, resulting in gross proceeds of $6 million before expenses [1]. - The underwriters have a 45-day option to purchase an additional 225,000 shares to cover over-allotments at the initial offering price [2]. - The shares began trading on the Nasdaq Capital Market under the symbol "ZGM" on September 9, 2025 [2]. Group 2: Use of Proceeds - Proceeds from the offering will be allocated towards business growth in Macau, Hong Kong, and Southeast Asia, development of the fintech business, brand development, team expansion, and general corporate purposes [3]. Group 3: Company Background - Zenta Group Company Limited, founded in 2019, is a diversified consulting and fintech solutions provider based in Macau, focusing on industrial park consultation, business investment consultation, and fintech products and services [7]. - The company primarily serves clients from China's Greater Bay Area, assisting them in navigating commercial project approvals and accessing fintech solutions [7].

Group 1 - The Producer Price Index (PPI) is a key focus for investors, as it measures costs on producers and has risen at a higher rate in July compared to Personal Consumption Expenditures (PCE) and the Consumer Price Index (CPI) [2] - The August PPI report is anticipated to be released at 8:30 a.m. ET, with expectations of a +0.3% year-over-year increase, which could influence market movements [3] - Klarna, a buy now pay later firm, is set to launch an upsized initial public offering (IPO), indicating ongoing interest in fintech IPOs [4] Group 2 - The market experienced excitement with a new record close for the S&P 500 and Nasdaq Composite, alongside significant news from Oracle and geopolitical events [4] - The market is closely monitoring the upcoming CPI release for August, which is due out the day after the PPI report [3]

As filed with the Securities and Exchange Commission on September 8, 2025. Registration No. 333-285692 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 4 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REGENTIS BIOMATERIALS LTD. (Exact name of registrant as specified in its charter) | State of Israel | 2834 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or orga ...